BLEPHAMIDE S.O.P. OINT Rx
Generic Name and Formulations:
Sulfacetamide sodium 10%, prednisolone acetate 0.2%.
Indications for BLEPHAMIDE S.O.P. OINT:
Ocular inflammation with infection.
Adults and Children:
<6yrs: not established. ≥6yrs: 2 drops every 4 hours and at bedtime or small amount of ointment 3–4 times daily and 1–2 times at night. May prolong dosing interval as condition improves; max 20mL or 8g per therapeutic course. Re-evaluate if no improvement after 2 days.
Ocular fungal, viral, or mycobacterial infections.
Corneal or scleral thinning: increased risk of perforation. Glaucoma. Severe dry eye. Purulent exudates may inactivate sulfonamides. Cataract surgery: may delay healing and increase bleb formation. May mask signs of infection. Monitor for secondary ocular infections (eg, fungal) and intraocular pressure in prolonged use (≥10 days). Discontinue if rash or hypersensitivity reactions occur. Avoid abrupt cessation. Pregnancy. Nursing mothers: not recommended.
Sulfonamide + steroid.
Incompatible with silver-containing preparations. Antagonized by PABA.
Ocular irritation, secondary ocular infections; rare: severe sulfonamide reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, blood dyscrasias). In prolonged use: increased IOP, cataracts, optic nerve damage.
Susp—5mL, 10mL; Oint—3.5g
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Whole Genome Sequencing Use in Predicting TB Resistance
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Interferon Alfa May Decrease the Incidence of Chronic HCV Infection
- Predicative Factors for Relapse in Adult Bacterial Osteomyelitis
- Supply Updates Announced for Recombivax HBV Vaccines
- Point-of-Care Testing Methods Compared for Influenza Detection
- Success With DAA for Hepatitis C Prior to Stem Cell Transplant